Literature DB >> 3544847

A case of the Neu-Laxova syndrome: prenatal ultrasonographic monitoring in the third trimester and the histopathological findings.

L M Muller, G de Jong, S C Mouton, M J Greeff, P Kirby, R Hewlett, H F Jordaan.   

Abstract

A diagnosis of the Neu-Laxova syndrome was made by ultrasonography in the third trimester of pregnancy. Initial ultrasonographic examination, at approximately 28 wk gestation, showed intrauterine growth retardation (IUGR), hypoechoic skeletal structures, kyphosis, feeble fetal activity, and restricted limb movement. Subsequent sonograms showed microcephaly with a receding forehead and prominent eyes, generalised edema and flexion deformities of limbs. Late third trimester findings included polyhydramnios, swelling and webbing of the knee and elbow joints, and severe edema of the hands and feet, giving the impression of absent digits. The clinical features of this case are consistent with group II of Curry's classification of the Neu-Laxova syndrome [Curry, 1982]. The histopathological findings, a triad of dermatological features, poor cortex formation of the long bones, and central nervous system (CNS) dysgenesis, are discussed. In view of the 25% recurrence rate, at risk pregnancies should be carefully monitored by ultrasonography: at 6-8 wk for accurate dating, at 12-16 weeks for active fetal limb movement, and at 16-24 wk for facial and skeletal anomalies, the detection of IUGR, and polyhydramnios.

Entities:  

Mesh:

Year:  1987        PMID: 3544847     DOI: 10.1002/ajmg.1320260221

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  2 in total

1.  Antley-Bixler syndrome: description of two patients.

Authors:  E Bianchi; S Cordini; P Fiori; F Torcetta; G Beluffi
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

2.  Prenatal diagnosis of Neu-Laxova syndrome: a case report.

Authors:  Halil Aslan; Ahmet Gul; Ibrahim Polat; Cihan Mutaf; Mehmet Agar; Yavuz Ceylan
Journal:  BMC Pregnancy Childbirth       Date:  2002       Impact factor: 3.007

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.